ArticleAlzheimer's & dementia (New York, N. Y.)2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design.
Article in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05153941 (DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)
Who cites it
16 citing papers in PubMed.
- Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.Alzheimer's research & therapy · 2021Trial
- Genetic variation in the glymphatic pathway predicts cognition and neurodegeneration in preclinical Alzheimer's disease.Research square · 2026Article
- Exploring the relationship between methylation of the cortisol receptor genes and brain and cognitive outcomes in individuals with elevated amyloid-β.Research square · 2025Article
- Amyloid pathology modulates the relationship between subsyndromal symptomatic depression and tau accumulation in non-demented older adults.Frontiers in aging neuroscience · 2025Article
- Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults.Frontiers in aging neuroscience · 2025Article
- Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.NPJ digital medicine · 2024Article
- Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.Neurology · 2024Article
- Discovery of novel CSF biomarkers to predict progression in dementia using machine learning.Scientific reports · 2023Article
- Association of Depressive Symptoms and Cognition in Older Adults Without Dementia Across Different Biomarker Profiles.Journal of Alzheimer's disease : JAD · 2022Article
- Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.Brain communications · 2022Article
- Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.Brain communications · 2022Article
- DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease.NeuroImage · 2021Article
- Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.The Journal of neuropsychiatry and clinical neurosciences · 2021Article
- Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease.BMC neurology · 2019Article
- Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET.Annals of clinical and translational neurology · 2019Article
- Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals.Annals of clinical and translational neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionWe investigated the influence of different inclusion criteria for preclinical and prodromal Alzheimer's disease (AD) on changes in biomarkers and cognitive markers and on trial sample size estimates.
methodsWe selected 522 cognitively normal subjects and 872 subjects with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative study. Compared inclusion criteria were (1) preclinical or prodromal AD (amyloid marker abnormal); (2) preclinical or prodromal AD stage-1 (amyloid marker abnormal, injury marker normal); and (3) preclinical or prodromal AD stage-2 (amyloid and injury markers abnormal). Outcome measures were amyloid, neuronal injury, and cognitive markers.
resultsIn both subjects with preclinical and prodromal AD stage-2, inclusion criteria resulted in the largest observed decline in brain volumetric measures on magnetic resonance imaging and cognitive markers. DISCUSSION: Inclusion criteria influence the observed rate of worsening in outcome measures. This has implications for trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.